Jody Charnow

The Department of Health and Human Services’ Office for Civil Rights is advising clinicians to take a closer look at their legacy IT systems and devices.

In a phase 3 trial of men with metastatic castration-resistant prostate cancer and altered DNA repair genes, olaparib-treated patients had significantly longer radiographic progression-free survival compared with enzalutamide or abiraterone recipients.